18,330 Shares in Inotiv, Inc. (NASDAQ:NOTV) Acquired by Virtu Financial LLC

Virtu Financial LLC acquired a new stake in Inotiv, Inc. (NASDAQ:NOTV) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 18,330 shares of the company’s stock, valued at approximately $76,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in NOTV. Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new stake in shares of Inotiv in the 4th quarter worth $60,000. AlphaCentric Advisors LLC acquired a new stake in shares of Inotiv in the 4th quarter worth approximately $163,000. Calamos Advisors LLC purchased a new position in shares of Inotiv in the fourth quarter valued at $275,000. Nkcfo LLC purchased a new position in Inotiv during the 4th quarter valued at about $476,000. Finally, Thurston Springer Miller Herd & Titak Inc. raised its position in shares of Inotiv by 612.5% during the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 127,257 shares of the company’s stock worth $527,000 after purchasing an additional 109,397 shares during the last quarter. 18.17% of the stock is owned by hedge funds and other institutional investors.

Inotiv Stock Up 2.8 %

Shares of NASDAQ:NOTV opened at $2.21 on Tuesday. The company has a market capitalization of $74.52 million, a P/E ratio of -0.48 and a beta of 3.77. The company has a quick ratio of 1.28, a current ratio of 1.57 and a debt-to-equity ratio of 2.31. The stock’s fifty day simple moving average is $3.48 and its 200-day simple moving average is $3.22. Inotiv, Inc. has a 52-week low of $1.23 and a 52-week high of $11.20.

Inotiv (NASDAQ:NOTV) last posted its quarterly earnings data on Wednesday, February 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.10). Inotiv had a negative return on equity of 15.41% and a negative net margin of 25.40%. As a group, equities research analysts forecast that Inotiv, Inc. will post -0.79 earnings per share for the current fiscal year.

Insider Buying and Selling at Inotiv

In other Inotiv news, CEO Robert Jr. Leasure sold 22,700 shares of the firm’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $4.15, for a total value of $94,205.00. Following the transaction, the chief executive officer now directly owns 1,030,209 shares of the company’s stock, valued at $4,275,367.35. This trade represents a 2.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold a total of 108,311 shares of company stock worth $425,330 in the last quarter. 7.80% of the stock is owned by insiders.

Inotiv Profile

Inotiv, Inc provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line.